A Phase III study of perioperative dostarlimab in patients with dMMR/MSI-H resectable colon cancer: AZUR-2 study design.
Naureen Starling, Elena Elez, John H Strickler...
https://pubmed.ncbi.nlm.nih.gov/41492912/Actively Recruiting
Led by GlaxoSmithKline · Updated on 2026-01-23
892
Participants Needed
266
Research Sites
105 weeks
Total Duration
Researchers are evaluating the efficacy of perioperative dostarlimab compared with the standard of care in participants with untreated T4N0 or Stage III resectable colon cancer that shows defective mismatch repair or high microsatellite instability dMMRMSI-H. This phase 3, open-label, randomized study focuses on these specific colon cancer patients to assess if dostarlimab can improve outcomes compared to current treatments. Participants are randomly assigned to receive either dostarlimab before and after surgery or the standard of care treatments, which include FOLFOX or CAPEOX chemotherapy or post-surgery observation. Dostarlimab is given as monotherapy during the perioperative period. The study carefully monitors participants for up to approximately 5 years to evaluate long-term effects. During the trial, participants undergo regular assessments including event-free survival reviewed by blinded independent central review, overall survival, and pathological response evaluations. Safety is closely monitored by tracking adverse events, immune-related effects, and serum concentrations of dostarlimab across treatment cycles. The study involves frequent follow-ups to understand treatment impact and ensure participant well-being throughout the extended observation period.
CONDITIONS
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
U
US GSK Clinical Trials Call Center
E
EU GSK Clinical Trials Call Center
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
GlaxoSmithKline
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Perioperative dostarlimab | Standard adjuvant chemotherapy |
|---|---|---|
| What it is | An investigational immunotherapy drug, dostarlimab, given before and after surgery as monotherapy. | Standard postoperative chemotherapy regimen using CAPEOX or FOLFOX after surgery. |
| Primary use or timing | Administered around the time of surgery (perioperative) to treat resectable dMMR/MSI‑H colon cancer. | Given after surgery as adjuvant chemotherapy to reduce recurrence risk. |
| Administration | Monotherapy dosing of dostarlimab given before and after surgical resection. | Post‑surgery chemotherapy using CAPEOX or FOLFOX for 3 to 6 months. |
| Evidence context | Efficacy is under study; based on the Phase III AZUR‑2 trial design. | Established adjuvant chemotherapy regimens with decades of evidence for reducing recurrence after surgery. |
| Limitations | Unproven new approach; benefit and safety are not yet established. | Chemotherapy may cause toxicity and long‑term side effects such as nerve damage. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Multiple cycles over several months as per protocol
Participants receive perioperative treatment with Dostarlimab or standard of care involving FOLFOX/CAPEOX chemotherapy or observation around the time of surgery.
Multiple visits for treatment cycles and surgery
Duration - Up to approximately 5 years
Participants are monitored for event-free and overall survival, adverse events, and other outcomes for up to approximately 5 years after treatment.
Periodic visits during follow-up
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Naureen Starling, Elena Elez, John H Strickler...
https://pubmed.ncbi.nlm.nih.gov/41492912/GlaxoSmithKline
Lead Sponsor